Trial · NCT00572897

Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis

NCT00572897, Phase 2, Completed, John Mascarenhas; results first posted 2016-05-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis. Trials, record NCT00572897. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00572897

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis
NCT number: NCT00572897
Status: Completed
Phases: Phase 2
Enrollment: 66 participants, actual
Lead sponsor: John Mascarenhas
Conditions: Myelofibrosis
Interventions: Fludarabine, Melphalan +/- ATG
First posted: 2007-12-13
Last updated: 2017-05-15
Results first posted: 2016-05-02

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	The Primary Endpoint is Progression-free Survival.	2 years	Number of participants alive at 2 years who are progression-free
Secondary	Response Outcomes	180 days	assessed according to the IWG Criteria
Secondary	Overall Survival	73 months	The number of patients alive at last follow-up.
Secondary	Absolute Neutrophil Count (ANC)	2 years	Patients with ANC ≥0.5 × 10\^9/L
Secondary	PLT	2 years	Patients with PLT ≥20 × 109/L
Secondary	Transplant-related Mortality	2 years	Transplant-related Mortality including Graft-versus-host disease (GVHD)

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	The Primary Endpoint is Progression-free Survival.	2 years		participants	NUMBER
SECONDARY	Response Outcomes	180 days	Clinical responses were assessed according to the IWG-MRT 2006 criteria in 46 patients (29 sibling and 17 unrelated transplants) who survived at least 180 days.	participants	NUMBER
SECONDARY	Overall Survival	73 months		participants	NUMBER
SECONDARY	Absolute Neutrophil Count (ANC)	2 years		participants	NUMBER
SECONDARY	PLT	2 years		participants	NUMBER
SECONDARY	Transplant-related Mortality	2 years		participants	NUMBER

Source ClinicalTrials.gov

Results by group26

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
The Primary Endpoint is Progression-free Survival.	Sibling Donor		24	participants
The Primary Endpoint is Progression-free Survival.	Unrelated Donor		11	participants
Response Outcomes	Sibling Donor	clinical complete response	7	participants
Response Outcomes	Unrelated Donor	clinical complete response	6	participants
Response Outcomes	Sibling Donor	clinical partial response	8	participants
Response Outcomes	Unrelated Donor	clinical partial response	1	participants
Response Outcomes	Sibling Donor	clinical improvement	11	participants
Response Outcomes	Unrelated Donor	clinical improvement	5	participants
Response Outcomes	Sibling Donor	stable disease	2	participants
Response Outcomes	Unrelated Donor	stable disease	4	participants

1 to 10 of 26Source ClinicalTrials.gov

See all 26 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Sibling Donor	32
Overall Study	STARTED	Unrelated Donor	34
Overall Study	COMPLETED	Sibling Donor	32
Overall Study	COMPLETED	Unrelated Donor	34
Overall Study	NOT COMPLETED	Sibling Donor	0
Overall Study	NOT COMPLETED	Unrelated Donor	0

Source ClinicalTrials.gov

Adverse events22

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
serious	Death	Blood and lymphatic system disorders	Sibling Donor	1	32	1
serious	Death	Blood and lymphatic system disorders	Unrelated Donor	3	34	3
serious	Death	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Sibling Donor	1	32	1
serious	Death	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Unrelated Donor	0	34	0
serious	Death	Immune system disorders	Sibling Donor	3	32	3
serious	Death	Immune system disorders	Unrelated Donor	5	34	5
serious	Death	Blood and lymphatic system disorders	Sibling Donor	1	32	1
serious	Death	Blood and lymphatic system disorders	Unrelated Donor	3	34	3
serious	Death	Respiratory, thoracic and mediastinal disorders	Sibling Donor	1	32	1
serious	Death	Respiratory, thoracic and mediastinal disorders	Unrelated Donor	2	34	2

1 to 10 of 22Source ClinicalTrials.gov

See all 22 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Sibling Donor
Total, all-cause mortality	Unrelated Donor
Total, other adverse events	Sibling Donor	0	0
Total, other adverse events	Unrelated Donor	0	0
Total, serious adverse events	Sibling Donor	8	32
Total, serious adverse events	Unrelated Donor	23	34

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
24963042	RESULT

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P01CA108671	Myeloproliferative Neoplasms-Research Consortium	HOFFMAN, RONALD	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	NATIONAL CANCER INSTITUTE	2006 to 2025

Source NIH RePORTER

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Sibling Donor vs Unrelated Donor: The Primary Endpoint is Progression-free Survival.	Trial comparisons
Sibling Donor vs Unrelated Donor: Overall Survival	Trial comparisons
Sibling Donor vs Unrelated Donor: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00572897

GET https://conductscience.org/api/trials/v1/NCT00572897/results?page=2

API reference For AI assistants